Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.VGX Pharmaceuticals has announced that it will terminate its internal development program of Pictovir, its drug candidate for HIV infection, to focus the company's product development efforts on DNA-based vaccines and therapies.
Subscribe to our email newsletter
The company’s decision is based on the following: lack of clinically significant antiviral effects at the doses tested to date as a single therapy; and availability of very few viable vaccine candidates for HIV.
The company also said that it will focus its efforts on DNA vaccines and therapies, including its preventative and therapeutic vaccine for HIV, Pennvax-B, which is a DNA-based vaccine in clinical trials and supported by the HIV Vaccines Trials Network.
Joseph Kim, president and CEO of VGX, said: “VGX will focus its valuable resources on programs that can create the greatest value for our company and our shareholders.”